GLP-1 Pills for Weight Loss: What Is Available in the UK

• Answers whether GLP-1 tablets are actually available in the UK and on what basis
• Explains the strict rules for taking an oral GLP-1, and why each rule exists
• Compares tablets and injections on the things that genuinely differ
• Separates prescription treatment from the weight loss pills sold online

The needle is the reason a lot of people never start. They read about the injections, decide they cannot face a weekly jab, and quietly stop looking. So a GLP-1 you swallow is a significant development, and one that is poorly explained almost everywhere.

It is easy to assume that a tablet must be a weaker option than an injection. But oral semaglutide acts on the same GLP-1 receptor as injectable semaglutide. The difference lies in how the medicine is formulated and absorbed, which is also why the tablet has specific instructions for taking it.

That engineering problem is also why oral GLP-1 comes with rules that a weekly injection does not. This page explains what these tablets are, whether they work, exactly how they have to be taken and why, and how they genuinely compare with injections.

Key things to know

• GLP-1 tablets exist in the UK and are prescription only. The MHRA is clear that medicines in this class can only be prescribed by a healthcare professional.
• They act on the same receptor as the injections, by mimicking a hormone your gut releases after eating.
• Absorption is the weak point, which is why the instructions about water, timing and food are strict rather than advisory.
• Tablets are taken every day, where most injections in this class are weekly.
• Wegovy tablets are prescription-only medicines in the UK. Products sold without a prescription should not be assumed to contain genuine semaglutide or another authorised GLP-1 medicine.

Are there GLP-1 tablets in the UK?

Yes.The oral and injectable formulations contain semaglutide, but their dosing instructions differ. The UK marketing authorisation for Wegovy tablets covers adults with an initial BMI of 30 or above, or a BMI of 27 to below 30 with at least one weight-related health condition. As of October 2026, the newly approved tablet is not available through the NHS, and its NHS use will depend on the relevant NICE evaluation and commissioning arrangements.

What a GLP-1 tablet is

The oral and injectable formulations contain semaglutide, but their dosing instructions differ. The UK marketing authorisation for Wegovy tablets covers adults with an initial BMI of 30 or above, or a BMI of 27 to below 30 with at least one weight-related health condition. As of October 2026, the newly approved tablet is not available through the NHS, and its NHS use will depend on the relevant NICE evaluation and commissioning arrangements.

This active ingredient is clinically tested and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in controlled settings alongside diet and lifestyle changes.

The MHRA describes GLP-1 medicines as helping people feel fuller by mimicking a natural hormone released after eating, which also helps to lower blood sugar levels and reduce food cravings. That applies to the tablet exactly as it applies to the pen.

How does oral GLP-1 work?

Three effects, working together rather than separately.

It acts on appetite signalling in the brain, which reduces hunger and the pull towards food between meals, helping you lose weight by encouraging fewer calories consumed. It slows how quickly the stomach empties, so a meal produces fullness that lasts longer, supporting a lower calorie intake. Additionally, it improves the insulin response to eating while reducing glucagon, which is why this class came out of diabetes medicine before its weight effects were licensed separately.

For many people, reduced hunger and increased fullness can make it easier to manage food intake. However, the effects vary, and the medicine does not remove every challenge associated with weight management.

That is the honest description of what changes, and it is identical whether the medicine arrived through your skin or your stomach. Wegovy tablets and Wegovy injections contain the same active ingredient, semaglutide, but they have different dosing instructions and should not be switched without guidance from a prescriber.

Why a GLP-1 tablet was difficult to make

This is the part that explains everything else, so it is worth two minutes.

Peptides are exactly what your digestive system exists to destroy. Stomach acid and enzymes break protein into fragments, which is what they are supposed to do to the protein in your dinner. A peptide swallowed in an ordinary tablet would be dismantled before it reached the bloodstream.

Solving that meant formulating the tablet to protect the active substance and get a usable amount absorbed through the stomach wall. It works, but the margin is narrow, and that narrowness is why the instructions are so specific. Anything sitting in your stomach at the same time competes with absorption.

If the needle is what has been stopping you, the tablet form of GLP-1 weight treatment removes that obstacle entirely. Treatment suitability depends on an individual clinical assessment.

Do GLP-1 pills work?

They act on the same receptor by the same mechanism as the injectable medicines in this class, and they are licensed on the basis of clinical trial evidence reviewed by the MHRA before approval. A medicine does not receive a UK marketing authorisation without that.

Weight loss varies between individuals, and no medicine guarantees a particular result. NICE has specific criteria for reviewing injectable semaglutide and other weight-management medicines. Because the oral Wegovy formulation has a separate and more recent authorisation, do not automatically apply an injectable treatment's NHS review criteria to the tablet without checking the relevant guidance.

What decides whether a tablet works for you

Two things, and only one of them is the medicine.

The first is whether you are a person this class helps, which is something only time on treatment reveals and which the six month review exists to establish.

The second is specific to the oral format: whether you take it correctly. Absorption is the narrow point in the chain, so a tablet taken with breakfast, or washed down with tea, or swallowed alongside other medicines, may deliver considerably less than one taken properly.

Taking the tablet incorrectly can reduce absorption and may affect how well it works. If the response is lower than expected, your prescriber can review how you take it, your treatment history and other possible explanations.

How to take an oral GLP-1

The exact instructions are set out in the patient information leaflet for the specific medicine you are prescribed, and that leaflet is the authority rather than any article. What follows is the shape those instructions take and, more usefully, the reason behind each one.

The rules, and why each one exists

1. Take it on an empty stomach, first thing. Food in the stomach competes with absorption. This is the rule that matters most.
2. Use only a small amount of plain water, up to 120 mL, as specified in the patient information leaflet. Follow the instructions carefully because the amount of water and the timing of food and other medicines can affect absorption.
3. Swallow it whole. Do not split, crush or chew it. The formulation is doing work that is destroyed if the tablet is broken.
4. Wait before eating, drinking or taking anything else. The leaflet gives a specific waiting period. Other medicines taken inside that window can reduce absorption, and so can breakfast.
5. Take it at the same time every day. Daily dosing holds up as a fixed habit attached to something you already do, because the one thing that reliably undermines a daily medicine is forgetting it.

None of that is fussiness. Every one of those rules traces back to the absorption problem described above.

Missed dose

If you miss a dose of Wegovy tablets, skip the missed dose and take your next dose the following day as usual. Do not take an extra tablet to make up for the missed dose. For any other oral GLP-1 medicine, follow the instructions in its own patient information leaflet.

If you are unsure, contact the prescribing service rather than guessing. This is where a daily tablet differs usefully from a weekly injection: a single missed daily dose is a much smaller event than a missed weekly one.

Weight loss tablets versus injections

Both formats deliver the same class of medicine. The honest comparison is not about which is stronger, it is about which fits the person taking it.

Which format suits which person

A daily tablet suits someone with a stable morning routine who will genuinely wait before breakfast, and someone for whom needles are a real barrier rather than a mild dislike.

A weekly injection suits someone whose mornings are chaotic, who eats at unpredictable times, or who would rather deal with treatment once and forget it for six days. Shift workers and frequent travellers often find the weekly rhythm easier to protect.

Neither is the correct answer in general. It is a practical question about your life, and a reasonable thing to raise at assessment.

Tablet versus injection effectiveness

This is where most pages overreach, so here is the careful version.

Both formats are licensed on their own trial evidence, assessed separately by the MHRA. Comparing them properly requires trials designed to compare them directly, and results from one medicine cannot be transferred to another. Anyone offering a simple ranking is guessing or selling.

What is safe to say is that the format you will actually take correctly is the one with a chance of working for you. Adherence is not a lesser consideration than potency; for a daily medicine it may be the larger one.

To see how the formats sit alongside each other and what each involves, you can review injectable and tablet treatments side by side. Your prescriber will determine the appropriate treatment.

GLP-1 tablet side effects

Common side effects

Gastrointestinal side effects are common with oral semaglutide. In the 64-week OASIS 4 trial, nausea was reported in 46.6% of participants taking oral semaglutide, diarrhoea in 17.6%, vomiting in 30.9% and constipation in 20.1%. Most events were mild to moderate, although some people discontinued treatment because of gastrointestinal symptoms.

Constipation, indigestion, burping, reduced appetite and tiredness are also frequently reported. These are usually most noticeable when treatment starts and after any dose change, and they commonly ease as the body adapts.

Less common but serious

The MHRA asks prescribers to discuss less common but serious risks including pancreatitis and gall bladder disorders. Inflammation of the pancreas has been reported with medicines in this class, including rare reports with serious or fatal outcomes.

Severe or persistent abdominal pain, particularly pain that reaches through to your back and comes with vomiting, needs urgent medical attention rather than a wait and see approach. Very rare cases of non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can cause sudden loss of vision, have been reported with semaglutide. Anyone experiencing sudden loss of vision should seek urgent ophthalmological assessment.

If you take insulin or a sulfonylurea for diabetes alongside a GLP-1 medicine, low blood glucose becomes a risk. The MHRA advises that where this occurs, patients should eat or drink something that will raise their blood sugar quickly and seek medical attention if symptoms persist.

Reporting a side effect

Suspected side effects can be reported through the MHRA Yellow Card scheme. You do not need to be certain the medicine caused the problem, and you do not need a healthcare professional to report on your behalf.

For a newer class of medicine this matters more than it sounds, because rare effects are usually detected after licensing rather than before it.

Who can have GLP-1 tablets in the UK

Eligibility is based on BMI and on whether you have a weight related health condition, and it is settled by assessment rather than by a number you can look up.

• A BMI at or above a defined threshold, which is higher where no other health condition is present.
• A lower threshold can apply where at least one weight related condition is present, such as high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes.
• Ethnicity is taken into account, because BMI does not carry the same risk at the same number across all populations.
• You must be an adult, and the assessment covers your full medical history.

NICE positions medicines as something to consider after dietary, exercise and behavioural approaches have been started and evaluated, and states that all medicines for weight management should be used alongside a reduced calorie diet and increased physical activity.

Who they are not suitable for

A proper assessment looks for reasons not to prescribe as carefully as reasons to.

Wegovy tablets should not be used during pregnancy or breastfeeding. Semaglutide should be discontinued at least two months before a planned pregnancy. A known allergy to semaglutide or any of the product's ingredients is a contraindication. A history of pancreatitis, severe gastrointestinal problems and other relevant medical conditions require individual assessment and may affect whether treatment is appropriate.

Other medicines matter too, and for the oral format they matter twice over: some interact with the medicine, and some interfere with its absorption if taken at the wrong time.

Prescription weight loss options in the UK

All are prescription only and all require an assessment. They differ in mechanism, format, side effect profile and eligibility criteria, so choosing between them is a clinical exercise rather than a ranking.

Weight loss pills that are not medicines

This deserves its own section, because the search term "weight loss pills" returns two completely different things and the difference matters enormously.

Prescription GLP-1 tablets are licensed medicines, assessed by the MHRA, supplied by a registered pharmacy against a prescription, with approved patient information in the box. Everything else sold as a weight loss pill, whether described as a supplement, a fat burner or a natural alternative, is not a GLP-1 medicine and does not contain one.

The MHRA is explicit that GLP-1 medicines should not be bought from unregulated sellers such as beauty salons or via social media, or from anywhere without a prior consultation with a healthcare professional. A product offered without a prescription is either not what it claims to be or is being supplied illegally. Neither is a risk worth taking with something you swallow every day.

Getting treatment safely

A legitimate UK service takes a full medical history including other medicines and conditions, verifies your identity and measurements rather than accepting whatever is typed in, has a prescriber review your request individually, dispenses from a pharmacy registered with the GPhC, and includes the approved patient information leaflet with your medicine. It also gives you a route back to a prescriber when something is not going well.

Treatment is designed to sit alongside the rest of the picture rather than to replace it, which is why NICE frames medicines as an addition to diet and activity. Weight loss guidance alongside prescribed treatment is the part that decides what happens after the first six months.

Medical Disclaimer

This article is general information about prescription only medicines and is not medical advice. It contains no dosing instructions and no dose escalation schedule, and it is not a substitute for a consultation with a qualified healthcare professional. These medicines should only be used under the supervision of an appropriately qualified prescriber and in line with the approved patient information leaflet supplied with your medicine.

Treatment suitability depends on an individual clinical assessment, and results vary between individuals. Seek urgent medical attention for severe or persistent abdominal pain, repeated vomiting, sudden changes in vision, or signs of an allergic reaction such as swelling of the face, lips or throat or difficulty breathing. Suspected side effects can be reported through the MHRA Yellow Card scheme.